Capricorn Fund Managers Ltd Invests $2.60 Million in Vera Therapeutics, Inc. $VERA

Capricorn Fund Managers Ltd bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 64,604 shares of the company’s stock, valued at approximately $2,599,000.

A number of other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the last quarter. Optimize Financial Inc increased its position in shares of Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after acquiring an additional 256 shares during the last quarter. Virtus Investment Advisers LLC increased its position in shares of Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after acquiring an additional 290 shares during the last quarter. Intech Investment Management LLC raised its holdings in Vera Therapeutics by 2.4% during the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after acquiring an additional 424 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Vera Therapeutics by 2.0% during the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after purchasing an additional 550 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on VERA. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a research report on Wednesday, March 11th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA opened at $42.91 on Wednesday. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $3.08 billion, a P/E ratio of -7.75 and a beta of 0.93. Vera Therapeutics, Inc. has a 12 month low of $19.07 and a 12 month high of $56.05. The stock has a 50 day moving average of $36.09 and a 200-day moving average of $41.43.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the company posted ($0.81) earnings per share. As a group, equities research analysts predict that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the completion of the sale, the chief executive officer owned 235,244 shares in the company, valued at approximately $10,362,498.20. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 59,951 shares of company stock valued at $2,392,387 over the last 90 days. 15.90% of the stock is owned by corporate insiders.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.